Synapse - Genitourinary Oncology Service

Search Within

Genitourinary Oncology Service

Results (5690)

Randomized controlled trial testing methylphenidate as treatment for fatigue in men with prostate cancer

Meeting Abstract

Roth, A. J.; Nelson, C. J.; Rosenfeld, B.; O'Shea, N.; Slovin, S.
Psycho-Oncology (2006)

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)

Meeting Abstract

Rosenberg, J. E.; Halabi, S.; Sanford, B. L.; Himelstein, A. L.; Atkins, J. N.; Hohl, R.; Seagren, S. L.; Bajorin, D. F.; Small, E. J.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Ronnen, E. A.; Kondagunta, G. V.; Lau, C.; Fischer, P.; Ginsberg, M. S.; Baum, M.; Kim, S. T.; Chen, I.; Baum, C. M.; Motzer, R. J.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition

Meeting Abstract

Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
EJC Supplements (2006)

Fulltext@MSK | Save

Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102

Meeting Abstract

Philips, G.; Sanford, B.; Halabi, S.; Bajorin, D.; Small, E. J.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastorna multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM)

Meeting Abstract

Nguyen, T. D.; Lassman, A. B.; Lis, E.; Rosen, N.; Shaffer, D. R.; Scher, H. I.; Deangelis, L. M.; Abrey, L. E.
Neuro-Oncology (2006)

Fulltext@MSK | Save

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-Α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
Annals of Oncology (2006)

Fulltext@MSK | Save

Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

Meeting Abstract

Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save